Bemarituzumab在晚期实体瘤及FGFR2b阳性胃食管腺癌中的I期爬坡与扩展研究
该I期开放标签多中心试验评估了Bemarituzumab在晚期实体瘤及FGFR2b过表达的胃食管腺癌(GEA)患者中的安全性、药代动力学和初步活性。在高FGFR2b过表达GEA患者中,确认的客观缓解率为17.9%(95% CI 6.1%–36.9%)。
要点
- Bemarituzumab在晚期实体瘤和GEA中总体耐受良好,未报告剂量限制性毒性。
- 推荐剂量为15 mg/kg每2周一次,基于安全性、耐受性、药代动力学和临床活性确定。
- 高FGFR2b过表达GEA患者中确认的客观缓解率为17.9%(95% CI 6.1%–36.9%)。
核心结论
- Bemarituzumab总体耐受良好,并在晚期GEA后线治疗中显示出单药活性。
研究设计与样本
- FPA144-001是一项I期、开放标签、多中心试验,包括剂量爬坡(1a部分:复发实体瘤,0.3–15 mg/kg;1b部分:晚期GEA)和剂量扩展(2部分:晚期GEA按FGFR2b过表达水平分4个队列,另1个FGFR2b过表达晚期膀胱癌队列)。
主要发现
- 未报告剂量限制性毒性,基于安全性、耐受性、药代动力学参数和临床活性确定推荐剂量为15 mg/kg每2周一次。
- 最常见的治疗相关不良事件(TRAEs)为疲劳(17.7%)、恶心(11.4%)和干眼(10.1%)。
- 3级TRAEs包括恶心(2例)以及贫血、中性粒细胞减少、AST升高、碱性磷酸酶升高、呕吐和输液反应(各1例)。
- 在28例接受≥10 mg/kg每2周一次且≥70天的患者中,3例(10.7%)报告可逆的2级角膜TRAEs;未报告≥4级TRAEs。
- 28例高FGFR2b过表达GEA患者中,5例(17.9%;95% CI 6.1%–36.9%)达到确认的部分缓解。
临床怎么用
- Bemarituzumab 15 mg/kg每2周一次可作为FGFR2b过表达晚期GEA后线治疗的候选方案,需关注角膜事件和胃肠道不良反应。
- 治疗期间应监测角膜相关不良事件,尤其是接受较高累积剂量或较长疗程的患者。
局限性
- 本研究为I期单臂试验,样本量小,疗效数据需进一步验证。
- 高FGFR2b过表达队列的缓解率基于小样本(28例),置信区间较宽。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the safety, pharmacokinetics, and preliminary activity of bemarituzumab in patients with FGFR2b-overexpressing gastric and gastroesophageal junction adenocarcinoma (GEA). PATIENTS AND METHODS: FPA144-001 was a phase I, open-label, multicenter trial consisting of the following 3 parts: part 1a involved dose escalation in patients with recurrent solid tumors at doses ranging from 0.3 to 15 mg/kg; part 1b involved dose escalation in patients with advanced-stage GEA; and part 2 involved dose expansion in patients with advanced-stage GEA that overexpressed FGFR2b at various levels (4 cohorts; high, medium, low, and no FGFR2b overexpression) and 1 cohort of patients with FGFR2b-overexpressing advanced-stage bladder cancer. RESULTS: Seventy-nine patients were enrolled; 19 were enrolled in part 1a, 8 in part 1b, and 52 in part 2. No dose-limiting toxicities were reported, and the recommended dose was identified as 15 mg/kg every 2 weeks based on safety, tolerability, pharmacokinetic parameters, and clinical activity. The most frequent treatment-related adverse events (TRAEs) were fatigue (17.7%), nausea (11.4%), and dry eye (10.1%). Grade 3 TRAEs included nausea (2 patients) and anemia, neutropenia, increased AST, increased alkaline phosphatase, vomiting, and an infusion reaction (1 patient each). Three (10.7%) of 28 patients assigned to a cohort receiving a dose of ≥ 10 mg/kg every 2 weeks for ≥ 70 days reported reversible grade 2 corneal TRAEs. No TRAEs of grade ≥ 4 were reported. Five (17.9%; 95% CI, 6.1% to 36.9%) of 28 patients with high FGFR2b-overexpressing GEA had a confirmed partial response. CONCLUSION: Overall, bemarituzumab seems to be well tolerated and demonstrated single-agent activity as late-line therapy in patients with advanced-stage GEA. Bemarituzumab is currently being evaluated in combination with chemotherapy in a phase III trial as front-line therapy for patients with high FGFR2b-overexpressing advanced-stage GEA.
引用
- Catenacci DVT, Rasco D, Lee J, et al. Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma. J Clin Oncol. 2020. PMID: 32167861. doi:10.1200/JCO.19.01834
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。